Lipocalin-2 as a Significant Biomarker in Psoriasis | ||
| The Egyptian Journal of Hospital Medicine | ||
| Article 164, Volume 92, Issue 1, July 2023, Pages 6553-6560 PDF (675.28 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/ejhm.2023.316254 | ||
| Abstract | ||
| Background: Psoriasis (Ps) is a chronic inflammatory skin disease characterized by well-defined erythematous plaques with silvery scales and now it is considered a systemic disease. Lipocalin-2 (LCN2) is a protein stored in the specific granules of neutrophils, acting as a pro-inflammatory mediator that enhances the release of many cytokines, including IL-6, IL-8, and CXCL10, which results in aggravation of the disease. Objective: The present study aimed at determination of the serum lipocalin-2 concentration and its correlation with degrees of itch, psoriatic arthritis (PsA) and body mass index (BMI) in psoriatic patients. Also, to correlate between level of lipocalin-2 and Ps severity using the Psoriasis Area and Severity Index (PASI) score. Methods: This study included 2 groups; healthy subjects as control group and psoriatic patients’ group and each group included 45 patients. The clinical assessment of Ps was done by using PASI score. Serum LCN2 was measured and correlated with manifestations and severity of psoriasis. Results: Psoriatic patients demonstrated a statistically significantly higher LCN2 concentration, in comparison with control group. There was a significantly higher LCN2 in psoriatic arthritis than in non-psoriatic arthritis. Serum LCN2 showed excellent accuracy. Best cut-off level of 17.9, sensitivity was 86.7%, specificity was 91.1%. This study showed that serum LCN2 showed fair accuracy AUC (AUC=0.745) for prediction of psoriatic arthritis Conclusion: High serum LCN2 concentrations in psoriatic patients are correlated with severity and particularly indicate disease activity. | ||
| Keywords | ||
| Psoriasis; Lipocalin-2; Psoriasis Area and Severity Index (PASI) score | ||
|
Statistics Article View: 116 PDF Download: 311 |
||
